Family-owned Zambon, an Italian pharmaceutical company specializing in diseases of the central nervous system (CNS), and Canadian pharmaceutical company Valeo Pharma have reached a licensing agreement to commercialize Xadago (safinamide).
The drug is labelled for use against Parkinson’s disease, as an adjunct to other therapies, in the USA, Europe and Switzerland. It is not currently approved for use in Canada.
Under the terms of the agreement, Valeo Pharma will be responsible for all regulatory, sales and marketing, quality, and distribution activities in Canada.
Valeo Pharma will pay Zambon undisclosed upfront, regulatory and commercial milestone payments as well as royalties on product sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze